Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2/PHASE3
43 participants
INTERVENTIONAL
2024-04-22
2024-09-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout
NCT05818085
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 in Healthy Subjects
NCT03906006
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of ABP-671 in Patients With Gout or Hyperuricemia
NCT04638543
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671
NCT04060173
Study to Investigate the Effects of Food on Relative Bioavailability of ABP-671 Tablets in Healthy Subjects
NCT04303039
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ABP-671
ABP-671
Participants who were randomized to any of the ABP-671 treatment groups in Part 1 or Part 2 of Study ABP-671-301 will continue to receive the same dose level and dosing regimen during the Treatment Period of this Extension Study.
Participants who were randomized to receive placebo in Part 1 or Part 2 of Study ABP-671-301 will receive ABP-671 during the Treatment Period of the Extension Study.
Allopurinol
Allopurinol
Participants who were randomized to receive allopurinol in Part 1 of Study ABP-671-301 will continue to receive allopurinol during the Treatment Period of the Extension Study.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ABP-671
Participants who were randomized to any of the ABP-671 treatment groups in Part 1 or Part 2 of Study ABP-671-301 will continue to receive the same dose level and dosing regimen during the Treatment Period of this Extension Study.
Participants who were randomized to receive placebo in Part 1 or Part 2 of Study ABP-671-301 will receive ABP-671 during the Treatment Period of the Extension Study.
Allopurinol
Participants who were randomized to receive allopurinol in Part 1 of Study ABP-671-301 will continue to receive allopurinol during the Treatment Period of the Extension Study.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Is planning to become pregnant or breastfeed during the study or within ≤30 days after the last dose of the study drug.
* Is intolerant or unwilling to take colchicine or naproxen.
19 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Atom Therapeutics Co., Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alliance for Multispecialty Research
Tempe, Arizona, United States
Tucson Neuroscience Research, LLC
Tucson, Arizona, United States
Anaheim Clinical Trials (Cenexel ACT)
Anaheim, California, United States
Center for Clinical Trials of Sacramento
Sacramento, California, United States
Access Research Institute
Brooksville, Florida, United States
Nature Coast Clinical Reasearch
Crystal River, Florida, United States
JY Research Institute Inc.
Cutler Bay, Florida, United States
Accel Clinical Research Site
DeLand, Florida, United States
Jacksonville Center for Clinical Research
Jacksonville, Florida, United States
A & D Doctor Center
Miami, Florida, United States
Bioclinical Research Alliance
Miami, Florida, United States
Cordova Research Institute
Miami, Florida, United States
Century Research LLC
Miami, Florida, United States
ITB Research
Miami, Florida, United States
Combined Research Orlando Phase I-IV
Orlando, Florida, United States
New Horizons Research
Palmetto Bay, Florida, United States
Advanced Clinical Research of Atlanta
Atlanta, Georgia, United States
Centricity Research
Columbus, Georgia, United States
Alliance for Multispecialty Research, LLC.
Newton, Kansas, United States
DelRicht Research
New Orleans, Louisiana, United States
AMR
New Orleans, Louisiana, United States
Annapolis Internal Medicine/CCT Research
Annapolis, Maryland, United States
DelRicht Research of Gulfport
Gulfport, Mississippi, United States
Quality Clinical Research, Inc
Omaha, Nebraska, United States
Santa Rosa Medical Center
Las Vegas, Nevada, United States
Inspire Santa Fe Medical Group
Santa Fe, New Mexico, United States
OnSite Clinical Solutions
Salisbury, North Carolina, United States
Altoona Center for Clinical Research
Duncansville, Pennsylvania, United States
ClinSearch
Chattanooga, Tennessee, United States
Medical Care/CCT
Elizabethton, Tennessee, United States
PanAmerican Clinical Research, LLC
Brownsville, Texas, United States
Quality Research Inc.
San Antonio, Texas, United States
Worldwide Clinical Trials
San Antonio, Texas, United States
Paratus Clinical Research Western Sydney
Blacktown, New South Wales, Australia
Emeritus Research Sydney
Botany, New South Wales, Australia
Paratus Clinical Research Central Coast
Kanwal, New South Wales, Australia
A R Houston Medical Pty Ltd
Kippa-Ring, Queensland, Australia
Emeritus Research Melbourne
Camberwell, Victoria, Australia
Austin Health - Repatriation Hospital
Heidelberg, Victoria, Australia
New Hospitals
Tbilisi, , Georgia
Evex Hospitals Caraps Medline
Tbilisi, , Georgia
Aversi Clini
Tbilisi, , Georgia
The First Medical Center
Tbilisi, , Georgia
Academician Vakhtang Bochorishvili Clinic
Tbilisi, , Georgia
Innova
Tbilisi, , Georgia
Clinical Research Center (CRC)
Guatemala City, , Guatemala
Clínica Médica Especializada en Medicina Interna y Reumatología (CREER)
Guatemala City, , Guatemala
Clínica Médica Especializada en Medicina Interna y Reumatología
Guatemala City, , Guatemala
Clínica Médica Especializada en Medicina Interna
Guatemala City, , Guatemala
Buddhist Dalin Tzu Chi General Hospital
Chiayi City, , Taiwan
Chang Gung Memorial Hospital CGMH
Kaohsiung City, , Taiwan
Chung Shan Medical Univ. Hospital
Taichung, , Taiwan
Cheng-Shin General Hospital
Taipei, , Taiwan
Chang Gung Memorial Hospital LinKou
Taoyuan District, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ABP-671-302
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.